Literature DB >> 8049421

Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.

C Gaucher1, J Diéval, C Mazurier.   

Abstract

Genetic studies were performed in two unrelated patients with the IIC phenotype of von Willebrand disease (vWD) characterized by the increased concentration of the protomeric form of von Willebrand factor (vWF). In patient B, the sequencing of both exons 15 and 16 of the vWF gene showed two sequence alterations: a 3-bp insertion in exon 15 resulting in the insertion of a Glycine at position 625 (625insGly) and a 2-bp deletion in exon 16 leading to a premature translational stop at codon 711 (711 ter), at the heterozygote state. Patient A was found homozygous for a single point mutation also localized in exon 15 and responsible for the substitution Cys623Trp. These candidate mutations were not found in a panel of 96 normal chromosomes, suggesting a causal relationship with IIC vWD phenotypic expression. The composite heterozygote or homozygote state of both patients supports the recessive mode of inheritance already described for this phenotype. Furthermore, the localization of these gene defects in the D2 domain of vWF propeptide, known to play an important role in vWF multimerization, provides another argument in favor of their causative effect regarding the peculiar multimeric pattern of vWF in these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049421

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Exponential size distribution of von Willebrand factor.

Authors:  Svenja Lippok; Tobias Obser; Jochen P Müller; Valentin K Stierle; Martin Benoit; Ulrich Budde; Reinhard Schneppenheim; Joachim O Rädler
Journal:  Biophys J       Date:  2013-09-03       Impact factor: 4.033

4.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

5.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

6.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

7.  Identification of a candidate missense mutation in a family with von Willebrand disease type IIC.

Authors:  R Schneppenheim; K B Thomas; S Krey; U Budde; U Jessat; A H Sutor; B Zieger
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

8.  Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage.

Authors:  S L Haberichter; A M Allmann; M A Jozwiak; R R Montgomery; J C Gill
Journal:  J Thromb Haemost       Date:  2009-01-17       Impact factor: 5.824

9.  Von Willebrand disease: an overview.

Authors:  K Pavani Bharati; U Ram Prashanth
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

10.  The role of exon 45 and 16 in the pathogenesis of Von Willebrand disease in Iranian Patients.

Authors:  M Nasiri; H Galehdari; M Darbouy; M Yavarian; B Keikhaee
Journal:  Iran J Ped Hematol Oncol       Date:  2012-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.